藥碼
CHE04
藥名
LabetaloL HCL 5 mg/mL, 5 mL/Amp
英文商品名
Chenday 針 25 mg/5 mL/Amp
中文商品名
壓泰定注射液
螢幕名
Chenday 針 25 mg/5 mL/Amp
劑型
Inj
規格
成分
藥理分類
β-Adrenergic Blocking Agents
健保碼
AC49550221
ATC碼
適應症
the emergency and rapid control of severe hypertension, including severe pregnancy-induced hypertension; and for use in anesthesia requiring blood pressure reduction.
藥理
Antihypertensive; Beta-Blocker With Alpha-Blocking Activity
藥動學
Onset of action : Within 5 minutes
Peak effect : 5 to 15 minutes
Duration : 16 to 18 hours (dose dependent)
Distribution :
Apparent Vd : Adults: 2.5 to 15.7 L/kg
Protein binding: ~50%
Metabolism : Hepatic, primarily via glucuronide conjugation; extensive first-pass effect.
Half-life elimination : ~5.5 hours
Excretion : Urine (55% to 60% as glucuronide conjugates, <5% as unchanged drug); feces (12% to 27% as metabolites)
Peak effect : 5 to 15 minutes
Duration : 16 to 18 hours (dose dependent)
Distribution :
Apparent Vd : Adults: 2.5 to 15.7 L/kg
Protein binding: ~50%
Metabolism : Hepatic, primarily via glucuronide conjugation; extensive first-pass effect.
Half-life elimination : ~5.5 hours
Excretion : Urine (55% to 60% as glucuronide conjugates, <5% as unchanged drug); feces (12% to 27% as metabolites)
禁忌症
Hypersensitivity (eg, anaphylaxis) to labetalol or any component of the formulation; severe sinus bradycardia; heart block greater than first degree; cardiogenic shock; bronchial asthma or obstructive airway disease; administration of non-dihydropyridine calcium channel blockers (eg, verapamil).
懷孕分類
Labetalol crosses the placenta.
Exposure to beta-blockers during pregnancy may increase the risk for adverse events in the neonate. If maternal use of a beta-blocker is needed, monitor fetal growth during pregnancy; monitor the newborn for 48 hours after delivery for bradycardia, hypoglycemia, and respiratory depression.
Exposure to beta-blockers during pregnancy may increase the risk for adverse events in the neonate. If maternal use of a beta-blocker is needed, monitor fetal growth during pregnancy; monitor the newborn for 48 hours after delivery for bradycardia, hypoglycemia, and respiratory depression.
哺乳分類
Peak breast milk concentrations are noted to occur 1 to 3 hours after the maternal dose.
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Labetalol is considered compatible for use in patients who are breastfeeding.
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Labetalol is considered compatible for use in patients who are breastfeeding.
副作用
劑量和給藥方法
Adults :
IV Bolus
Administer 50 mg IV over at least 1 minute for rapid blood pressure reduction. If necessary, repeat every 5 minutes until the desired response is achieved.
Maximum total dose: 200 mg.
Onset of maximal effect is usually within 5 minutes; duration of action is generally approximately 6 hours.
IV Infusion
Dilute to a concentration of 1 mg/mL and infuse at approximately 160 mg/hour, adjusting the rate according to clinical response.
Pregnancy-induced hypertension : Start at 20 mg/hour and double the infusion rate every 30 minutes until a satisfactory response is achieved or 160 mg/hour is reached.
Hypertension due to other causes : Start at 120–160 mg/hour and discontinue once the desired response is achieved. The usual effective dose is 50–200 mg; higher doses may be required, particularly in patients with pheochromocytoma.
Controlled Hypotension During Anesthesia
Administer 10–20 mg IV initially; 25–30 mg may be required when halothane is contraindicated.
If adequate blood pressure reduction is not achieved after 5 minutes, additional 5–10 mg doses may be given as needed. When used with halothane, the halothane concentration should generally not exceed 1–1.5% due to additive hypotensive effects.
IV Bolus
Administer 50 mg IV over at least 1 minute for rapid blood pressure reduction. If necessary, repeat every 5 minutes until the desired response is achieved.
Maximum total dose: 200 mg.
Onset of maximal effect is usually within 5 minutes; duration of action is generally approximately 6 hours.
IV Infusion
Dilute to a concentration of 1 mg/mL and infuse at approximately 160 mg/hour, adjusting the rate according to clinical response.
Controlled Hypotension During Anesthesia
Administer 10–20 mg IV initially; 25–30 mg may be required when halothane is contraindicated.
If adequate blood pressure reduction is not achieved after 5 minutes, additional 5–10 mg doses may be given as needed. When used with halothane, the halothane concentration should generally not exceed 1–1.5% due to additive hypotensive effects.
小兒調整劑量
IV (intermittent bolus) : Children and Adolescents: 0.2 to 1 mg/kg/dose; maximum dose: 40 mg/dose.
Continuous IV infusion : Infants, Children, and Adolescents: 0.25 to 3 mg/kg/hour; initiate at lower end of range and titrate up slowly to effect. In one retrospective study in infants and children 24 months of age, reductions in blood pressure were observed at doses up to 0.59 mg/kg/hour, with little additional benefit at higher doses.
腎功能調整劑量
No dosage adjustment necessary.
肝功能調整劑量
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage reduction may be necessary in hepatic impairment due to decreased metabolism and increased oral bioavailability, use with caution.
安定性
Store below 30℃ away from light.
藥袋資訊
臨床用途
高血壓
主要副作用
頭暈、鼻塞、疲倦、噁心、皮疹
泡製方法
儲存方式
請置於 15-30℃ 乾燥處儲存
注意事項
其他說明
急首 d2 | 藥庫 注C11
藥品外觀
顏色
形狀
剝痕
標記1
標記2
其他
健保藥價
68
自費價
90.44
仿單
資料庫
健保給付規定
## 資料使用與著作權聲明 本網站提供之藥品資訊，主要供醫療照護、藥事服務、衛教及一般資訊查詢使用。網站內容包含藥品名稱、成分、劑型、規格、適應症、使用方式、劑量、注意事項及其他相關資訊，實際內容依各藥品資料來源及本院資料建置情形而定。 一、醫療使用聲明 本網站所提供之藥品資訊僅供參考，不應單獨作為診斷、治療、處方調整、停藥或自行用藥之依據。 藥品之實際適應症、使用方法、使用劑量、使用頻率、療程及相關注意事項，應依個別病人之病情、年齡、肝腎功能、合併用藥及其他臨床狀況，由醫師或其他具資格之醫療專業人員進行專業判斷。 病人實際使用藥品時，請以醫師處方、藥袋標示及醫療專業人員之指示為依歸。請勿僅依本網站資訊自行增加、減少、停止或改變藥品使用方式及劑量。 如網站資訊與醫師處方、藥袋標示或醫療專業人員指示有所不同，應優先依醫師處方及醫療專業人員之個別指示使用。 二、資料來源與更新 本網站藥品資訊參考藥品資訊資料庫、主管機關核准之藥品仿單、藥品許可證資料、藥品製造或供應廠商提供之資料、本院藥品管理資料，以及其他經評估之專業資訊來源。 藥品資訊可能因主管機關核准內容、藥品許可證、仿單、供應狀況或臨床建議更新而有所變動，本網站將依實際作業情形進行維護與更新。 如需確認最新藥品核准資訊，應以主管機關公告、最新版藥品仿單及醫療專業人員判斷為準。 三、資料使用範圍 本網站內容可供個人查詢、醫療照護、衛教及非商業性學習使用。 使用者引用或轉載本網站內容時，應註明資料來源，並保留原有內容之完整性及必要之醫療警語，不得任意變更、變更原意或其他可能造成錯誤醫療理解之方式使用。 未經授權，不得將本網站內容大量重製、建立資料庫、進行商業性再利用，或以其他方式侵害相關著作權或其他權利。 四、著作權及第三方資料 本網站由本院自行製作之文字、編排、圖表、圖示及其他內容，其著作權或相關權利依著作權法及其他相關法令受到保護。 網站中引用之藥品仿單、藥品圖片、商標、產品名稱、主管機關資料或其他第三方資料，其著作權、商標權或其他相關權利仍歸原權利人所有。 本網站對第三方資料之使用，以醫療資訊提供、教育、研究或其他合法使用目的為原則，相關權利仍應依原資料來源及相關法令辦理。 五、責任範圍 本網站致力於維持資料之正確性與完整性，但藥品資訊可能隨核准事項、臨床資訊及供應狀況變更。 使用者因個別疾病、用藥或治療問題需要醫療判斷時，應洽詢醫師、藥師或其他適當之醫療專業人員。 本網站提供之一般性藥品資訊，無法取代醫療專業人員依個別病人狀況所作之醫療評估、處方及用藥指導。 六、聲明內容之調整 本院得依相關法令、資料來源、網站功能及實際作業需要，適時修訂本聲明內容。